136 related articles for article (PubMed ID: 3361581)
1. Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides.
Tucker H; Crook JW; Chesterson GJ
J Med Chem; 1988 May; 31(5):954-9. PubMed ID: 3361581
[TBL] [Abstract][Full Text] [Related]
2. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen.
Furr BJ; Valcaccia B; Curry B; Woodburn JR; Chesterson G; Tucker H
J Endocrinol; 1987 Jun; 113(3):R7-9. PubMed ID: 3625091
[TBL] [Abstract][Full Text] [Related]
3. Resolution of the nonsteroidal antiandrogen 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'- (trifluoromethyl)-propionanilide and the determination of the absolute configuration of the active enantiomer.
Tucker H; Chesterson GJ
J Med Chem; 1988 Apr; 31(4):885-7. PubMed ID: 3351865
[TBL] [Abstract][Full Text] [Related]
4. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
Furr BJ
Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
[No Abstract] [Full Text] [Related]
5. Evaluation of a peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat.
Chandolia RK; Weinbauer GF; Behre HM; Nieschlag E
J Steroid Biochem Mol Biol; 1991 Mar; 38(3):367-75. PubMed ID: 1848993
[TBL] [Abstract][Full Text] [Related]
6. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring.
Kirkovsky L; Mukherjee A; Yin D; Dalton JT; Miller DD
J Med Chem; 2000 Feb; 43(4):581-90. PubMed ID: 10691684
[TBL] [Abstract][Full Text] [Related]
7. [Anti-androgenic activity of various substituted carboxyanilides].
Varga SV; Reznikov AG; Bal'on IaG; Lozinskiĭ MO; Smirnov VA
Probl Endokrinol (Mosk); 1983; 29(2):67-71. PubMed ID: 6856597
[TBL] [Abstract][Full Text] [Related]
8. Flutamide. Mechanism of action of a new nonsteroidal antiandrogen.
Sufrin G; Coffey DS
Invest Urol; 1976 May; 13(6):429-34. PubMed ID: 1270239
[TBL] [Abstract][Full Text] [Related]
9. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
Freeman SN; Mainwaring WI; Furr BJ
Br J Cancer; 1989 Nov; 60(5):664-8. PubMed ID: 2803943
[TBL] [Abstract][Full Text] [Related]
10. Biological aspects of antiandrogens.
Neri RO; Peets EA
J Steroid Biochem; 1975 Jun; 6(6):815-9. PubMed ID: 1177425
[No Abstract] [Full Text] [Related]
11. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Akakura K; Furuya Y; Ito H
Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
[TBL] [Abstract][Full Text] [Related]
12. Effect of antiandrogens casodex and epitestosterone on bone composition in mice.
Broulik PD; Stárka L
Bone; 1997 May; 20(5):473-5. PubMed ID: 9145245
[TBL] [Abstract][Full Text] [Related]
13. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.
Edwards JP; West SJ; Pooley CL; Marschke KB; Farmer LJ; Jones TK
Bioorg Med Chem Lett; 1998 Apr; 8(7):745-50. PubMed ID: 9871534
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
[TBL] [Abstract][Full Text] [Related]
15. The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening.
Lanter JC; Fiordeliso JJ; Jiang W; Allan GF; Lai MT; Linton O; Hahn do W; Lundeen SG; Sui Z
Bioorg Med Chem Lett; 2007 Jan; 17(1):123-6. PubMed ID: 17071085
[TBL] [Abstract][Full Text] [Related]
16. Effects of androgens and antiandrogens on the quantitative immunohistochemistry of gonadotrope cells in prepubertal male rats.
Cónsole GG; Rulli SB; Riccillo FL; Calandra RS; Gómez Dumm CL
Neuroendocrinology; 1999 Oct; 70(4):261-7. PubMed ID: 10529621
[TBL] [Abstract][Full Text] [Related]
17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
18. 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists.
Ng RA; Guan J; Alford VC; Lanter JC; Allan GF; Sbriscia T; Lundeen SG; Sui Z
Bioorg Med Chem Lett; 2007 Feb; 17(4):955-8. PubMed ID: 17134895
[TBL] [Abstract][Full Text] [Related]
19. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor.
He Y; Yin D; Perera M; Kirkovsky L; Stourman N; Li W; Dalton JT; Miller DD
Eur J Med Chem; 2002 Aug; 37(8):619-34. PubMed ID: 12161060
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
